SEARCH RESULTS

1227 RESULTS

In Phase 2 Trial, Neflamapimod Aids Cognition in Lewy Body Dementia

CONFERENCE COVERAGE 2020-11-21 Conference Coverage If at first you don’t succeed, try, try again. This adage seemed to pay off for the clinical development of the drug neflamapimod. After failing to curb cognitive decline in people with AD, the drug appears to have done just that in ...

Learning Troubles Spied by Smartphone Track with Biomarkers

CONFERENCE COVERAGE 2020-11-20 Conference Coverage When it comes to teasing out the earliest whiffs of cognitive impairment, nothing beats a comprehensive in-person exam at the memory clinic … right? Well, that may be changing. New findings presented at the Clinical Trials in Alzheimer ...

TRC-PAD Funnel Finally Touches Down

CONFERENCE COVERAGE 2020-11-17 Conference Coverage Part 3 of 3 Recruiting asymptomatic participants for secondary prevention trials such as AHEAD 3-45 is no small feat. How do you find people who are well on the road to Alzheimer’s disease but feel fine, thank you very much? Scientists ...

BAN2401 Forges AHEAD into Phase 3, Preclinical AD

CONFERENCE COVERAGE 2020-11-17 Conference Coverage Part 2 of 3 As data from Phase 2 open-label extension studies is trickling in (see Part 1 of this story), the true test of BAN2401’s efficacy in both the early and preclinical stages of Alzheimer’s disease begins. In presentations at ...

BANish Aβ? BAN2401 Antibody Makes Its Move in Phase 3 Program

CONFERENCE COVERAGE 2020-11-17 Conference Coverage Part 1 of 3 While much of the Alzheimer’s world was enthralled by the drama of the FDA advisory committee’s shellacking of aducanumab’s application for marketing approval (Nov 2020 news) the Clinical Trials in Alzheimer’s Disease (CTAD ...

At AAIC, Hints of Target Engagement for Some Drug Candidates

CONFERENCE COVERAGE 2020-08-12 Conference Coverage This year’s virtual Alzheimer’s Association International Conference featured no new efficacy data from large clinical trials, but there were some snippets of news from early phase studies. CT1812 by Cognition Therapeutics (CogRx) ...

Umibecestat-Driven Cognitive Decline Is Reversible

CONFERENCE COVERAGE 2020-08-12 Conference Coverage At this year’s virtual Alzheimer’s Association International Conference, researchers from Novartis and the Banner Alzheimer’s Institute presented highly anticipated follow-up data from the massive Generation 1 and 2 Phase 3 trials. ...

Heart Health Is Brain Health, and It Starts in Your 20s

CONFERENCE COVERAGE 2020-08-07 Conference Coverage Having established that poor cardiovascular health in midlife increases the risk of cognitive decline and dementia as a person ages, scientists are now pushing to see if the same relationship might hold true even earlier in life. ...

Lancet Commission’s Dementia Hit List Adds Alcohol, Pollution, TBI

CONFERENCE COVERAGE 2020-08-04 Conference Coverage At this year’s virtual Alzheimer’s Association International Conference, researchers presented an update to “Dementia prevention, intervention, and care,” the 2017 report commissioned by The Lancet. Published July 30, the new report ...

IDEAS Finds Small Drop in Hospitalizations, Missing Goal

CONFERENCE COVERAGE 2020-08-01 Conference Coverage Numerous studies have now found that amyloid PET scans can alter a person’s diagnosis and disease management—but do they reduce overall medical costs? According to data from the final phase of the IDEAS study, presented at the virtual ...

Doubling Down on Sequencing Serves up More Alzheimer’s Genes

CONFERENCE COVERAGE 2020-07-31 Conference Coverage The list of rare and common genetic variants that sway a person’s risk of Alzheimer’s disease just got substantially longer, as researchers expanded both the breadth and depth of genomic studies aimed at uncovering the etiology of the ...

Could Common Vaccines Protect Against Alzheimer’s Disease?

CONFERENCE COVERAGE 2020-07-29 Conference Coverage During a viral pandemic, everything to do with vaccination is au courant. At this week’s virtual Alzheimer’s Association International Conference, two reports drew attention by turning on its head the field’s emerging research trend ...

Plasma p-Tau217 Set to Transform Alzheimer’s Diagnostics

CONFERENCE COVERAGE 2020-07-29 Conference Coverage Suddenly, phospho-tau217 looks to be the most robust plasma biomarker for Alzheimer’s disease yet. That’s the general—and enthusiastic—consensus from two papers and several presentations at this year’s virtual Alzheimer’s Association ...

α-Synuclein Antibody Misses Primary, May Have Signal on Secondaries

CONFERENCE COVERAGE 2020-04-22 Conference Coverage Roche and Prothena today announced  topline results from the first half of their Phase 2 trial of the α-synuclein antibody prasinezumab. Results were negative on the MDS-UPDRS, the primary outcome measure, but the company said it saw ...

Current Filters

  • Conference Coverage x
  • TYPE: News x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE
TYPE OF NEWS
DISEASE
TOPIC
BIOMOLECULE